Real-life evidence of encorafenib plus binimetinib in patients with unresectable advanced or metastatic BRAF(V600)-mutant melanoma in Spain: the BECARE (GEM-2002) trial.

Soria A, Sanchez Mauriño P, Serrano Domingo JJ, García Galindo R, Sequero S, Gutiérrez Sanz L, Crespo G, Díaz-Beveridge R, Puértolas T, López P, Fra Rodríguez J, López Castro R, Aguayo C, Valdivia J, Cunquero-Tomás AJ, Benítez G, Ayala de Miguel P, Espinosa E, Muñoz-Couselo E, Campos B, García Sánchez L, Cerezuela-Fuentes P

Open source

DOI: 10.3389/fonc.2025.1466185
Published: 2025
Container: Frontiers in oncology
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fonc.2025.1466185,
  title = {Real-life evidence of encorafenib plus binimetinib in patients with unresectable advanced or metastatic BRAF(V600)-mutant melanoma in Spain: the BECARE (GEM-2002) trial.},
  author = {Soria A and Sanchez Mauriño P and Serrano Domingo JJ and García Galindo R and Sequero S and Gutiérrez Sanz L and Crespo G and Díaz-Beveridge R and Puértolas T and López P and Fra Rodríguez J and López Castro R and Aguayo C and Valdivia J and Cunquero-Tomás AJ and Benítez G and Ayala de Miguel P and Espinosa E and Muñoz-Couselo E and Campos B and García Sánchez L and Cerezuela-Fuentes P},
  year = {2025},
  journal = {Frontiers in oncology},
  doi = {10.3389/fonc.2025.1466185},
  url = {https://doi.org/10.3389/fonc.2025.1466185}
}

RIS

TY  - JOUR
TI  - Real-life evidence of encorafenib plus binimetinib in patients with unresectable advanced or metastatic BRAF(V600)-mutant melanoma in Spain: the BECARE (GEM-2002) trial.
AU  - Soria A
AU  - Sanchez Mauriño P
AU  - Serrano Domingo JJ
AU  - García Galindo R
AU  - Sequero S
AU  - Gutiérrez Sanz L
AU  - Crespo G
AU  - Díaz-Beveridge R
AU  - Puértolas T
AU  - López P
AU  - Fra Rodríguez J
AU  - López Castro R
AU  - Aguayo C
AU  - Valdivia J
AU  - Cunquero-Tomás AJ
AU  - Benítez G
AU  - Ayala de Miguel P
AU  - Espinosa E
AU  - Muñoz-Couselo E
AU  - Campos B
AU  - García Sánchez L
AU  - Cerezuela-Fuentes P
PY  - 2025
JO  - Frontiers in oncology
DO  - 10.3389/fonc.2025.1466185
UR  - https://doi.org/10.3389/fonc.2025.1466185
ER  -

APA

A, S., P, S. M., JJ, S. D., R, G. G., S, S., L, G. S., G, C., R, D., T, P., P, L., J, F. R., R, L. C., C, A., J, V., AJ, C., G, B., P, A. D. M., E, E., E, M., B, C., L, G. S., & P, C. (2025). Real-life evidence of encorafenib plus binimetinib in patients with unresectable advanced or metastatic BRAF(V600)-mutant melanoma in Spain: the BECARE (GEM-2002) trial.. Frontiers in oncology. https://doi.org/10.3389/fonc.2025.1466185

Source records

pubmed · retrieved 2026-09-27T07:01:04.145Z
europe-pmc · retrieved 2026-09-27T07:01:04.131Z
doaj · retrieved 2026-09-27T07:01:04.150Z